Clinical Research Directory

Inclusion Criteria: A diagnosis of CCUS: * Persistent cytopenia for \> 6 months defined as hgb \< 11.3 g/dL (7 mmol/L) in women and hgb \< 12.9 g/dL (8 mmol/L) in men, thrombocyte count \< 150 x 10\^9/L or neutrophil count \< 1.8 x 10\^9/L * Normal cytogenetics (with the exception of deletion of the Y chromosome which can be accepted) * A bone marrow morphology that is not diagnostic of MDS or any other malignancy * Other common causes of cytopenia (vitamin or other deficiencies, virus infection, etc.) have been ruled out * Hematolytic conditions have been ruled out * The presence of a detectable mutation in genes recurrently affected in myeloid malignancy representing a clonal marker (excluding germline mutations) OR A diagnosis of MDS as according to World Health Organization (WHO) 2016 diagnostic criteria • Revised international prognostic scoring system (IPSS-R) risk score ≤ 3 AND bone marrow blast percentage \< 5 defining low-risk OR A diagnosis of CMML-0 or -1 as according to WHO 2016 diagnostic criteria AND (All diagnostic categories) The presence of a detectable mutation in genes recurrently affected in myeloid malignancy representing a clonal marker (excluding germline mutations) Exclusion Criteria: * Unwillingness to discontinue any and all use of vitamin C medication/supplementation including multivitamin at least 24 hours prior to Baseline investigations and sampling * Lack of ability to understand the information given, or lack of willingness to sign a written informed consent document * Treatment with chemotherapy within the past 6 months * Patients receiving active treatment for their myeloid malignancy, including investigational agents, with the exception of granulocyte colony-stimulating factor (G-CSF) and erythropoietin * History of allergic reactions to ascorbic acid * Unwillingness to comply with all aspects of the protocol